Progress towards measles and rubella elimination--Indonesia, 2013-2022/Progres realises en vue d'eliminer la rougeole et la rubeole--Indonesie, 2013-2022

In 2019, Indonesia and the other countries in the WHO South-East Asia Region adopted the goal of measles and rubella elimination by 2023. This report describes Indonesia's progress during 2013-2022. Coverage with a first dose of measles-containing vaccine (MCV) decreased from 87% to 84%, and coverage with a second MCV dose decreased from 76% to 67%. After rubella vaccine was introduced in 2017, coverage with the first dose of rubella-containing vaccine increased by 5 times, from 15% in 2017 to 84% in 2022. During 2013-2021, the annual reported measles incidence decreased by 95%, from 33.2 to 1.4 cases per million population, and the reported rubella incidence decreased by 89%, from 9.3 to 1.0 cases per million population. A large upsurge in measles and rubella cases occurred in 2022, however, with a reported measles incidence of 29 cases per million population and a reported rubella incidence of 3 per million, due primarily to the disruption in immunization services by the coronavirus disease 2019 (COVID-19) pandemic. In 2022, >26 million children (an estimated 73% of the target population) received a combined measles- and rubella-containing vaccine (measles and rubella CV) during supplementary immunization activities in 32 provinces. Although progress has been made towards measles and rubella elimination in Indonesia, continued and urgent efforts are necessary to restore routine immunization services and to close gaps in order to accelerate progress towards elimination. En 2019, l'Indonesie et les autres pays de la Region OMS de l'Asie du Sud-Est ont adopte l'objectif d'eliminer la rougeole et la rubeole d'ici a 2023. Le present rapport decrit les progres realises par l'Indonesie sur la periode 2013-2022. La couverture par la premiere dose de vaccin a valence rougeole (MCV) a baisse, passant de 87% a 84%, de meme que la couverture par la deuxieme dose de MCV, qui est passee de 76% a 67%. Apres l'introduction du vaccin contre la rubeole en 2017, la couverture par la premiere dose du vaccin a valence rubeole a ete multipliee par 5, passant de 15% en 2017 a 84% en 2022. Entre 2013 et 2021, d'apres les donnees qui ont ete communiquees, l'incidence annuelle de la rougeole a diminue de 95%, passant de 33,2 a 1,4 cas par million d'habitants, et l'incidence de la rubeole a baisse de 89%, passant de 9,3 a 1,0 cas par million d'habitants. Une forte recrudescence de cas de rougeole et de rubeole s'est toutefois produite en 2022, oU l'incidence de la rougeole etait de 29 cas par million d'habitants et l'incidence de rubeole de 3 cas par million d'habitants, principalement en raison de la perturbation des services de vaccination par la pandemie de maladie a coronavirus 2019 (COVID-19). En 2022, >26 millions d'enfants (environ 73% de la population cible) ont recu le vaccin combine antirougeoleux-antirubeoleux (MRCV) lors des activites de vaccination supplementaire menees dans 32 provinces. Bien que des progres vers l'elimination de la rougeole et de la rubeole aient ete accomplis en Indonesie, il est urgent de retablir les services de vaccination systematique et de combler les lacunes afin de parvenir plus rapidement a l'elimination de ces maladies.
Introduction Indonesia's immunization programme currently targets a birth cohort of over 4.4 million children annually. In 1982, a first dose of measles-containing vaccine (MCV1) was introduced into the routine immunization [...]